TAAR1 and schizophrenia: While there is limited publicly available information on ralmitaront’s preclinical profile [22], ulotaront is designated as a promiscuous TAAR1 and 5-HT1A agonist [23,24] that is proving able to control the positive, negative, and cognitive symptoms of schizophrenia [25,26].